1-(1-溴乙基)-2,4-二氯苯 | 20444-01-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(1-溴乙基)-2,4-二氯苯
• 英文名称: 1-(1-bromoethyl)-2,4-dichlorobenzene
• 英文别名: 1-(1-bromo-ethyl)-2,4-dichloro-benzene；1-(1-Brom-aethyl)-2,4-dichlor-benzol；1-(2.4-Dichlor-phenyl)-ethylbromid
• CAS: 20444-01-3
• 化学式: C₈H₇BrCl₂
• mdl: MFCD11103119
• 分子量: 253.954
• InChiKey: YXQINLRLOBXZTF-UHFFFAOYSA-N

物化性质

• 沸点：
  266.3±25.0 °C(Predicted)
• 密度：
  1.586±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  1-(1-溴乙基)-2,4-二氯苯 、 alkaline earth salt of/the/ methylsulfuric acid 生成 2,4-二氯-α-甲基苯甲醇
  参考文献：
  名称：

  Evans; Mabbott; Turner, Journal of the Chemical Society, 1927, p. 1165

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4-二氯苯乙酮 在 N-溴代丁二酰亚胺(NBS) 、 一水合肼 、 过氧化苯甲酰 作用下， 反应 2.0h， 生成 1-(1-溴乙基)-2,4-二氯苯
  参考文献：
  名称：

  Intramolecular nucleophilic participation. VI. Forced carbomethoxy group participation in the solvolysis of 1-(2,6-dicarbomethoxyphenyl)ethyl bromide

  摘要：

  DOI：

  10.1021/ja01015a033

文献信息

• [EN] AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSES AMINOHETEROARYLES EN TANT QU'INHIBITEURS DES PROTEINES TYROSINE KINASES
  申请人：PFIZER

  公开号：WO2006021886A1

  公开（公告）日：2006-03-02

  Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

  提供了氨基杂环芳基化合物，以及它们的合成和使用方法。优选化合物是c-Met蛋白激酶的强效抑制剂，并且在治疗异常细胞生长紊乱，如癌症方面具有用处。
• [EN] 1-ALKYL-PYRAZOLES AND -INDAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES<br/>[FR] 1-ALKYL-PYRAZOLES ET 1-ALKYL-INDAZOLES UTILISÉS EN TANT QU'INHIBITEURS DE BUB1 POUR LE TRAITEMENT DE MALADIES HYPERPROLIFÉRATIVES
  申请人：BAYER PHARMA AG

  公开号：WO2017157991A1

  公开（公告）日：2017-09-21

  Compounds of formula (I) and their use as pharmaceuticals.

  化合物的化学式（I）及其作为药物的用途。
• [EN] IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ AMÉLIORÉ DE PRÉPARATION D'AMBRISENTAN ET NOUVEAUX INTERMÉDIAIRES ASSOCIÉS
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2011004402A2

  公开（公告）日：2011-01-13

  The invention relates to improved processes for the preparation of ambrisentan. The invention also relates to a novel intermediate useful in the preparation of ambrisentan and a process for the preparation of the intermediate. The invention also relates to new polymorphic form of ambrisentan. In particular, it relates to a polymorphic form, designated as Form I of ambrisentan and a process for the preparation of the Form I.

  本发明涉及改进的阿布利生坦制备过程。本发明还涉及一种新型中间体，可用于制备阿布利生坦的过程。本发明还涉及阿布利生坦的新多晶形态。特别地，本发明涉及一种多晶形态，称为阿布利生坦的I型，以及制备I型的过程。
• Aminoheteroaryl compounds as protein kinase inhibitors
  申请人：Cui Jean Jingrong

  公开号：US20060178374A1

  公开（公告）日：2006-08-10

  Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

  提供了氨基杂环芳基化合物，以及它们的合成和使用方法。优选化合物是c-Met蛋白激酶的强力抑制剂，并且在治疗异常细胞生长障碍，如癌症方面非常有用。
• 3-pyrazolecarboxamide derivatives having cannabinoid receptor affinity
  申请人：Sanofi

  公开号：US05925768A1

  公开（公告）日：1999-07-20

  The present invention relates to compounds of the formula ##STR1## in which: X.sub.1 is a group --NR.sub.1 R.sub.2 or a group --OR.sub.2 ; g.sub.2, g.sub.3, g.sub.4, g.sub.5, g.sub.6 and w.sub.2, w.sub.3, w.sub.4, w.sub.5, w.sub.6 are identical or different and are each independently hydrogen, a halogen atom, a (C.sub.1 -C.sub.4)alkyl, a (C.sub.1 -C.sub.4)alkoxy, a trifluoromethyl, a nitro or a (C.sub.1 -C.sub.4)alkylthio, with the proviso that at least one of the substituents g.sub.2, g.sub.3, g.sub.4, g.sub.5, g.sub.6 and at least one of the substituents w.sub.2, w.sub.3, w.sub.4, w.sub.5, w.sub.6 are other than hydrogen; R.sub.1 is hydrogen or a (C.sub.1 -C.sub.4)alkyl; R.sub.2 is a non-aromatic (C.sub.3 -C.sub.15)carbocyclic radical which is unsubstituted or monosubstituted or polysubstituted by a substituent selected from a halogen atom, a (C.sub.1 -C.sub.4)alkyl and a (C.sub.1 -C.sub.4)alkoxy; R.sub.3 is hydrogen or a group --CH.sub.2 R.sub.6 ; and R.sub.4 and R.sub.5 are each independently a hydrogen, a (C.sub.1 -C.sub.4)alkyl or a trifluoromethyl; or else R.sub.4 is hydrogen and R.sub.5 and w.sub.6 together constitute an ethylene or trimethylene radical; and R.sub.6 is hydrogen, a (C.sub.1 -C.sub.4)alkyl, a fluorine, a hydroxyl, a (C.sub.1 -C.sub.5)alkoxy, a (C.sub.1 -C.sub.5)alkylthio, a hydroxy(C.sub.1 -C.sub.5)alkoxy, a cyano, a (C.sub.1 -C.sub.5)alkylsulfinyl or a (C.sub.1 -C.sub.5)alkylsulfonyl with the proviso that when the substituents g.sub.2, g.sub.3, g.sub.4, g.sub.5 and/or g.sub.6 are a (C.sub.1 -C.sub.4)alkyl R.sub.6 is only hydrogen; to a process for their preparation and to the pharmaceutical compositions in which they are present. These compounds have a good affinity for the peripheral cannabinoid receptors.

  本发明涉及以下公式的化合物：##STR1## 其中：X.sub.1是一个基团--NR.sub.1 R.sub.2或一个基团--OR.sub.2；g.sub.2，g.sub.3，g.sub.4，g.sub.5，g.sub.6和w.sub.2，w.sub.3，w.sub.4，w.sub.5，w.sub.6相同或不同，每个独立地为氢、卤素原子、(C.sub.1-C.sub.4)烷基、(C.sub.1-C.sub.4)烷氧基、三氟甲基、硝基或(C.sub.1-C.sub.4)烷基硫醇，但要求至少有一个取代基g.sub.2，g.sub.3，g.sub.4，g.sub.5，g.sub.6和至少有一个取代基w.sub.2，w.sub.3，w.sub.4，w.sub.5，w.sub.6不是氢；R.sub.1是氢或(C.sub.1-C.sub.4)烷基；R.sub.2是非芳香性(C.sub.3-C.sub.15)碳环基，未取代或单取代或多取代，所述取代基选自卤素原子、(C.sub.1-C.sub.4)烷基和(C.sub.1-C.sub.4)烷氧基；R.sub.3是氢或基团--CH.sub.2 R.sub.6；R.sub.4和R.sub.5各自独立地为氢、(C.sub.1-C.sub.4)烷基或三氟甲基；否则，R.sub.4是氢，而R.sub.5和w.sub.6共同构成乙烯或三亚甲基基团；R.sub.6是氢、(C.sub.1-C.sub.4)烷基、氟、羟基、(C.sub.1-C.sub.5)烷氧基、(C.sub.1-C.sub.5)烷硫基、羟基(C.sub.1-C.sub.5)烷氧基、氰基、(C.sub.1-C.sub.5)烷基亚砜或(C.sub.1-C.sub.5)烷基磺酰基，但要求当取代基g.sub.2，g.sub.3，g.sub.4，g.sub.5和/或g.sub.6为(C.sub.1-C.sub.4)烷基时，R.sub.6仅为氢；以及制备它们的过程和它们存在的药物组合物。这些化合物具有与周围的大麻素受体良好的亲和力。